Vanta Bioscience Key Ratios
BSE: 540729
₹19.64
₹-1.03
(-4.98%)
As on 13-Aug-2026IST
Market cap
₹14 Cr
Revenue (TTM)
₹2 Cr
P/E Ratio
129.3
P/B Ratio
1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -79.80 | -41.26 | -32.25 |
| EBIT | -- | -- | -172.37 | -259.13 | -222.22 |
| Net Profit | -- | -- | -54.42 | -562.11 | -267.34 |
| EPS | -- | -- | -106.18 | -478.33 | -236.59 |
| Book Value | -- | -- | -31.42 | -24.28 | -14.98 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| -63.67 | -101.09 | -441.66 | -32.75 | -80.69 |
| Net Margin
| -100.15 | -174.47 | -640.68 | -87.56 | -150.00 |
| Return on equity
| -11.17 | -40.84 | -103.74 | -52.62 | -50.31 |
| Return on Capital
| -0.48 | -2.34 | -10.93 | -4.08 | -6.10 |
| Return on Assets
| -4.36 | -7.45 | -15.52 | -10.12 | -12.57 |
| Debt to Equity (x)
| -- | -- | 6.72 | 4.01 | 3.26 |
Profitability
ROCE
-10.93
Lower than Peers by 25.65
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-10.93
|
-4.08
|
-6.10
|
4.00
|
5.42
|
|
Peer Median
|
14.72
|
18.85
|
11.60
|
11.89
|
--
|
ROE
-103.74
Lower than Peers by 115.41
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-103.74
|
-52.62
|
-50.31
|
0.56
|
1.89
|
|
Peer Median
|
11.67
|
14.92
|
11.46
|
13.43
|
--
|
ROA
-15.52
Lower than Peers by 23.38
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-15.52
|
-10.12
|
-12.57
|
0.18
|
0.76
|
|
Peer Median
|
7.86
|
9.06
|
6.44
|
7.03
|
--
|
EBIT Margin
-441.66
Lower than Peers by 456.69
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-441.66
|
-32.75
|
-80.69
|
22.22
|
27.45
|
|
Peer Median
|
15.03
|
14.71
|
12.37
|
16.50
|
--
|
Net Margin
-640.68
Lower than Peers by 650.01
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-640.68
|
-87.56
|
-150.00
|
1.33
|
4.55
|
|
Peer Median
|
9.33
|
8.49
|
10.02
|
10.49
|
--
|
Cash Profit Margin
-451.95
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-451.95
|
-42.27
|
-123.88
|
14.98
|
16.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-79.80
Lower than Peers by 90.07
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-79.80
|
54.92
|
-35.22
|
-1.30
|
-28.63
|
|
Peer Median
|
10.27
|
11.85
|
9.08
|
13.45
|
--
|
EBIT Growth
-172.37
Lower than Peers by 196.52
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-172.37
|
37.13
|
-335.30
|
-20.12
|
-15.28
|
|
Peer Median
|
24.15
|
28.00
|
-3.12
|
18.27
|
--
|
Net Profit Growth
-54.42
Lower than Peers by 84.71
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-54.42
|
17.60
|
-7,855.72
|
-69.96
|
-55.73
|
|
Peer Median
|
30.29
|
36.51
|
-0.85
|
27.20
|
--
|
EPS Growth
-106.18
Lower than Peers by 130.68
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-106.18
|
64.26
|
-7,449.46
|
-80.38
|
-55.25
|
|
Peer Median
|
24.50
|
--
|
-6.82
|
16.28
|
--
|
Book Value Growth
-31.42
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-31.42
|
-13.22
|
-27.04
|
0.37
|
1.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
6.72
Higher than Peers by 6.50
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
6.72
|
4.01
|
3.26
|
1.87
|
1.50
|
|
Peer Median
|
0.23
|
0.20
|
0.15
|
0.15
|
--
|
Short term debt to equity ratio
0.80
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
0.80
|
0.35
|
0.21
|
0.13
|
0.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.58
Lower than Peers by 1.21
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
0.58
|
0.75
|
0.86
|
1.02
|
1.34
|
|
Peer Median
|
1.79
|
1.96
|
2.08
|
1.89
|
--
|
Quick Ratio
0.33
Lower than Peers by 1.13
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
0.33
|
0.42
|
0.46
|
0.51
|
0.69
|
|
Peer Median
|
1.47
|
1.44
|
1.58
|
1.64
|
--
|
Interest Coverage
-2.10
Lower than Peers by 11.53
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-2.10
|
-0.54
|
-0.74
|
1.10
|
1.28
|
|
Peer Median
|
9.42
|
8.58
|
15.41
|
15.38
|
--
|
Operating Efficiency
Debtors to sales
127.48
Higher than Peers by 101.66
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
127.48
|
32.30
|
31.21
|
11.71
|
20.53
|
|
Peer Median
|
25.82
|
26.12
|
22.96
|
20.72
|
--
|
Asset Turnover
0.02
Lower than Peers by 0.73
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
0.02
|
0.11
|
0.08
|
0.13
|
0.17
|
|
Peer Median
|
0.75
|
0.77
|
0.65
|
0.61
|
--
|
Receivable days
524.58
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
524.58
|
95.72
|
89.94
|
59.32
|
61.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
1,303.78
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
1,303.78
|
275.51
|
418.55
|
320.25
|
432.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
1,437.15
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
1,437.15
|
2,480.59
|
1,287.00
|
761.36
|
213.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
391.21
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
391.21
|
-2,109.35
|
-778.52
|
-381.79
|
281.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
--
|
--
|
--
|
786.33
|
228.87
|
|
Peer Median
|
39.70
|
33.48
|
37.74
|
60.11
|
--
|
Price / Book Value
1.34
Lower than Peers by 2.38
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
1.34
|
2.66
|
2.07
|
2.89
|
4.30
|
|
Peer Median
|
3.72
|
4.21
|
3.22
|
3.92
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.16
|
0.21
|
0.57
|
0.56
|
--
|
EV/EBITDA
-20.22
Lower than Peers by 50.45
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
-20.22
|
71.30
|
-54.70
|
29.29
|
34.22
|
|
Peer Median
|
30.23
|
29.90
|
28.81
|
25.94
|
--
|
Market Cap
14
Lower than Peers by 4,837
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Vanta Bioscience
|
14
|
40
|
36
|
69
|
103
|
|
Peer Median
|
4,851
|
2,099
|
15,272
|
13,501
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
